Jose Carmona Net Worth

The estimated Net Worth of Jose Carmona is at least $27 mil dollars as of 26 February 2020. Mr. Carmona owns over 1,292 units of Rubius Therapeutics Inc stock worth over $3,877 and over the last 8 years he sold RUBY stock worth over $23,166. In addition, he makes $0 as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer y Treasurer at Rubius Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Carmona RUBY stock SEC Form 4 insiders trading

Jose has made over 2 trades of the Rubius Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 1,292 units of RUBY stock worth $23,166 on 26 February 2020.

The largest trade he's ever made was buying 3,000 units of Rubius Therapeutics Inc stock on 14 September 2017 worth over $98,490. On average, Jose trades about 537 units every 112 days since 2017. As of 26 February 2020 he still owns at least 46,708 units of Rubius Therapeutics Inc stock.

You can see the complete history of Mr. Carmona stock trades at the bottom of the page.

Jose Carmona biography

Jose Carmona has been appointed as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer of the Company effective 10/1/2020. Prior to his appointment, Mr. Carmona served as the Chief Financial Officer of Radius Health, Inc. (“Radius”), a biopharmaceutical company that is developing and commercializing endocrine therapeutics, from 2017 to 2020. Prior to Radius, Mr. Carmona served as the Chief Financial Officer of Innocoll Holdings plc (“Innocoll”), a pharmaceutical and medical device company, and its predecessor entity, Innocoll AG, from 2015 to 2017. Prior to Innocoll, he served as Chief Financial Officer of Alcon Europe, Middle East & Africa, a division of Novartis AG (“Novartis”), a pharmaceutical company, from 2013 to 2015 and prior to that he held numerous financial management positions with increasing responsibility at Novartis, as Divisional Chief Financial Officer in North America, Latin America and other senior global financial roles, from 2003 to 2013. Mr. Carmona received his B.S. in Industrial Civil Engineering from Universidad Tecnica Federico Santa Maria in Valparaiso, Chile, and his M.B.A. from Columbia Business School in New York City.

How old is Jose Carmona?

Jose Carmona is 48, he's been the Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer y Treasurer of Rubius Therapeutics Inc since 2020. There are 14 older and 3 younger executives at Rubius Therapeutics Inc. The oldest executive at Rubius Therapeutics Inc is Michael Rosenblatt, 69, who is the Independent Director.

What's Jose Carmona's mailing address?

Jose's mailing address filed with the SEC is C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE, MA, 02139.

Insiders trading at Rubius Therapeutics Inc

Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz y Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $2,709. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.

What does Rubius Therapeutics Inc do?

developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.

Complete history of Mr. Carmona stock trades at Radius Recycling y Rubius Therapeutics Inc

Rubius Therapeutics Inc executives and stock owners

Rubius Therapeutics Inc executives and other stock owners filed with the SEC include:

• Pablo Cagnoni,
  President, Chief Executive Officer, Director
• Maiken Keson-Brookes,
  Chief Legal Officer, Corporate Secretary
• Dr. Pablo J. Cagnoni M.D., Ph.D.,
  CEO, Pres & Director
• David Epstein,
  Chairman of the Board
• Laurence A. Turka M.D.,
  Chief Scientific Officer and Head of Research & Translational Medicine
• Natalie Holles,
  Independent Director
• David R. Epstein B.Sc., M.B.A.,
  Exec. Chairman
• Dannielle Appelhans,
  Chief Operating Officer
• Anne Prener,
  Independent Director
• Jonathan Symonds,
  Independent Director
• Francis Cuss,
  Independent Director
• Catherine Sohn,
  Independent Director
• Noubar Afeyan,
  Independent Director
• Michael Rosenblatt,
  Independent Director
• Lori Melancon,
  IR Contact Officer
• Christina Coughlin,
  Chief Medical Officer
• Greg ..,
  Chief Quality Officer
• Laurence Turka,
  Chief Scientific Officer
• Kris Elverum,
  Senior Vice President - Business Development and Strategy
• Jose Carmona,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
• Jill Murray,
  VP & Head of HR
• Marissa Hanify,
  Director of Corp. Communications
• Maiken Keson-Brookes,
  Chief Legal Officer & Corp. Sec.
• Elhan Webb C.F.A.,
  VP of Investor Relations
• Mark J. Hernon,
  Chief Information Officer
• Spencer Fisk,
  Sr. VP & Chief Technical Operations Officer
• Jose I. Carmona,
  CFO, Principal Accounting Officer & Treasurer
• Ventures Fund Iv General Pa...,
  
• Susanne Schaffert,
  Director
• Robert Langer,
  Director
• Roger Pomerantz,
  Director
• Ventures Fund Iv General Pa...,
  
• Torben Straight Nissen,
  President
• Christopher L. Carpenter,
  Chief Medical Officer
• Dannielle Appelhans,
  CEO and President